Advancing outcomes in CP-CML: Guideline-directed approaches to treatment decision-making, monitoring and toxicity management

touchPANEL DISCUSSION for touchHAEMATOLOGY and touchONCOLOGY Listen to leading experts discuss guideline-directed strategies for mutational analysis and monitoring response when treating patients with chronic-phase chronic myeloid leukaemia with approved tyrosine kinase inhibitors. The experts Dr Jorge Cortes, Georgia Cancer Center, Augusta, GA, USA Dr Elias Jabbour, MD Anderson Cancer Center, Houston, TX, USA  Dr Vivian Oehler, Fred Hutch Cancer Center, Seattle, WA, USA This touchPODCAST is for HCPs in the USA only. This activity is funded by an independent medical education grant from Takeda Development Center Americas, Inc. Jointly provided by Partners for Advancing Clinical Education and touchIME. For further information, visit our websites:  www.touchHAEMATOLOGY.com www.touchONCOLOGY.com